Medicines and ethics

Poor-quality medicines are especially prevalent in low- and middle-income countries. They represent a threat for individual and public health. Under-dosed products or insufficiently bio-available drugs can cause therapeutic failure, and they can also provoke the emergence of resistances (e.g. in the case of anti-malarials). ‘Repressive’ measures may help fight falsified medicines, which are illegal but they will do little to stop the circulation of substandard medicines, which requires sustained capacity strengthening of regulators and sensitize all concerned stakeholders, manufacturers and purchasers.

ITM manages a scientific portfolio focusing on access to quality-assured medicines in low- and middle-income countries, in close collaboration with several partners, for example the QUAMED group, and in strict collaboration with Be-cause health. Our specific activities include policy development, research, advocacy, networking and education
Clinical trials are more and more delocalised to low- and middle-income countries, often to address the local health needs. It is of paramount importance that all these trials are methodologically and ethically sound, and responsive to the needs of communities. 

We animate the informal network of clinical researchers that previously operated under the framework of the Switching the Poles Network. We stimulate exchange of view, scientific collaborations and ethical reflection.